Advanced Search

Oncology & Hematology Coding Alert

Reader Questions:

Keep V58.11 for Antineoplastic Agent

Published on Fri Jan 19, 2007

Question: When I use a chemo admin code for a drug that isn't chemo (such as Remicade or IVIG), should I still report V58.11? Washington Subscriber Answer: No. You should report V58.11 (Encounter for antineoplastic chemotherapy) only for patients receiving chemotherapy. If you report a chemotherapy code for antineoplastic immunotherapy, you may report V58.12 (Encounter for antineoplastic immunotherapy) instead. If you use a chemotherapy code for a substance that is not antineoplastic, such as Remicade, you should not use either V58.11 or V58.12.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All